sign in · help · news · about ·

BibSonomy :: user :: kanefendt ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

>
|
<

bookmarks

bookmarks per page: 5 10 20 50 100

RSS BibTeX RDF more

publications

(20)

<< < 1 > >>

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
E. Kapiteijn, A. Brand, J. Kroep, and H. Gelderblom Ann.Oncol. 18(10):1745-1747 (2007)
to & A Aged Agents Antineoplastic Endothelial Factor Female Growth Humans Hypertension Indoles Middle Neurotoxicity Purpura Pyrroles Receptor-2 Syndromes Thrombocytopenic Thrombotic Vascular adverse antagonists chemically effects etiology induced inhibitors by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Sunitinib efficacy against advanced renal cell carcinoma
R. J. Motzer, M. D. Michaelson, J. Rosenberg, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, and G. Wilding J.Urol. 178(5):1883-1887 (2007)
to & Administration Adult Aged Agents Antineoplastic Carcinoma Cell Disease Disease-Free Female Follow-Up Humans Indoles Kidney Laboratories Male Method Middle Neoplasm Neoplasms Oral Outcome Progression Pyrroles Rate Renal Research Retrospective Single-Blind Staging States Studies Survival Treatment Tyrosine United administration dosage drug epidemiology methods mortality pathology response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu, M. A. Rupnick, R. Kerkela, S. M. Dallabrida, D. Zurakowski, L. Nguyen, K. Woulfe, E. Pravda, F. Cassiola, J. Desai, S. George, J. A. Morgan, D. M. Harris, N. S. Ismail, J. H. Chen, F. J. Schoen, A. D. van den Abbeele, G. D. Demetri, T. Force, and M. H. Chen Lancet 370(9604):2011-2019 (2007)
to & Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib
E. Chorianopoulos, D. Jager, H. A. Katus, and N. Frey Clin.Res.Cardiol. 96(11):829-830 (2007)
to & Aged Agents Angiogenesis Antineoplastic Carcinoma Cardiomyopathies Cell Dysfunction Echocardiography Female Humans Illness Index Indoles Inhibitors Kidney Kinase Kinases Left Neoplasms Protein-Tyrosine Pyrroles Renal Severity Tyrosine Ventricular adverse antagonists chemically contraindications drug effects induced inhibitors of therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Angiogenesis: an organizing principle for drug discovery?
J. Folkman Nat.Rev.Drug Discov. 6(4):273-286 (2007)
to Agents Angiogenesis Animals Antineoplastic Blood Endothelium Humans Inhibitors Neoplasms Neovascularization Pathologic Physiologic Platelets RANGE Research drug effects genetics pathology pharmacology physiology therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)
to & A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Notch signaling in the regulation of tumor angiogenesis
A. O. Rehman, and C. Y. Wang Trends Cell Biol. 16(6):293-300 (2006)
to & Agents Angiogenesis Animals Binding Biological Blood Carcinogens Cells Endothelial Genes Humans Inducing Inhibitors Laboratories Ligands Models Neoplasms Neovascularization Notch Pathologic Receptors Signal Suppressor Transduction Tumor Vessels blood cells development growth metabolism physiology supply therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
H. M. Verheul, and H. M. Pinedo Nat.Rev.Cancer 7(6):475-485 (2007)
to & A Administration Agents Angiogenesis Antineoplastic Biological Blood Clinical Coagulation Drug Endothelial Factor Function Growth Humans Hypertension Inhibitors Left Models Neoplasm Platelets Research Resistance Schedule Signal Thrombosis Topic Transduction Trials Vascular Ventricular administration adverse antagonists as chemically dosage drug effects etiology induced inhibitors physiology toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Home blood-pressure monitoring in patients receiving sunitinib
M. Azizi, A. Chedid, and S. Oudard N.Engl.J.Med. 358(1):95-97 (2008)
to Agents Ambulatory Angiogenesis Antineoplastic Blood Carcinoma Cell Heart Home Humans Hypertension Indoles Inhibitors Kidney Kinase Kinases Monitoring Neoplasms Nursing Pressure Protein-Tyrosine Pyrroles Rate Receptor Renal Telemedicine adverse chemically diagnosis drug effects induced therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Validation of analytic methods for biomarkers used in drug development
C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg Clin.Cancer Res. 14(19):5967-5976 (2008)
to Agents Animals Antineoplastic Biological Biomarkers Chemistry Design Drug Evaluation Genome Genomics Human Humans Markers Medical Mice Neoplasms Oncology Outcome Pharmaceutical Pharmacological Preclinical Research Treatment Tumor analysis drug metabolism methods pharmacology therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Biomarker method validation in anticancer drug development
J. Cummings, T. H. Ward, A. Greystoke, M. Ranson, and C. Dive Br.J.Pharmacol. 153(4):646-656 (2008)
to & Adherence Agents Animals Antineoplastic Assay Biomarkers Cell Clinical Control Death Drug Enzyme-Linked Europe Evaluation Guideline Guidelines Humans Immunosorbent Keratin-18 Laboratories Mass Pharmacological Preclinical Proteins Quality Reproducibility Research Results Spectrometry Terminology Topic Trials analysis as drug effects jurisprudence legislation methods of pharmacology protein standards therapeutic use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller J Clin Oncol 26(11):1810-1816 (2008)
to & Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway
J. M. Roodhart, M. H. Langenberg, E. Witteveen, and E. E. Voest Curr.Clin.Pharmacol. 3(2):132-143 (2008)
to & A Agents Angiogenesis Animals Antibodies Antineoplastic Blood Coagulation Diseases Disorders Endothelial Factor Growth Humans Hypertension Hypothyroidism Inhibitors Intestinal Medical Nervous Oncology Perforation Proteinuria Receptors Signal System Transduction Tyrosine Vascular adverse antagonists chemically drug effects induced inhibitors pathology therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase I dose escalation study of telatinib BAY 57-9352 in patients with advanced solid tumours
D. Strumberg, B. Schultheis, I. A. Adamietz, O. Christensen, M. Buechert, J. Kraetzschmar, P. Rajagopalan, M. Ludwig, A. Frost, S. Steinbild, M. E. Scheulen, and K. Mross Br.J.Cancer 99(10):1579-1585 (2008)
to & 80 Adult Aged Agents Angiogenesis Antineoplastic Carcinoma Dose Female Growth Humans Hypertension Imaging Inhibitors Magnetic Male Maximum Medical Middle Neoplasms Oncology Plasma Pyridazines Pyridines RANGE Resonance Tolerated Tyrosine administration and blood dosage drug over response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Anti-VEGF therapy: the search for clinical biomarkers
R. Longo, and G. Gasparini Expert.Rev.Mol.Diagn. 8(3):301-314 (2008)
to & A Agents Angiogenesis Animals Antibodies Antineoplastic Biological Cells Diagnostic Endothelial Factor Growth Human Humans Imaging Inhibitors Markers Medical Monoclonal Neoplasms Oncology Piperazines Prognosis Pyrimidines Tumor Vascular antagonists cells diagnosis drug identify inhibitors metabolism methods pathology protein response therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2
W. Roeckl, D. Hecht, H. Sztajer, J. Waltenberger, A. Yayon, and H. A. Weich Exp.Cell Res. 241(1):161-170 (1998)
to & A Agents Animals BALB Binding C Cell Cells Cloning Competitive Cross-Linking Dimerization Endothelial Expression Factor Factors Fibrinolytic Gene Growth Heparin Human Humans Inbred Kinase Kinases Ligands Lymphokines Mice Mitogens Molecular Plastics Proliferation Protein Protein-Tyrosine Proteins Proto-Oncogene Reagents Receptor Receptor-1 Receptors Research Solubility Tyrosine Vascular antagonists cells drug effects genetics inhibitors isolation metabolism pharmacology protein purification by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation
A. Woywodt, J. Scheer, L. Hambach, S. Buchholz, A. Ganser, H. Haller, B. Hertenstein, and M. Haubitz Blood 103(9):3603-3605 (2004)
to Adult Aged Agents Antineoplastic Case-Control Cell Cells Conditioning Count Diseases Endothelial Endothelium Factors Female Hematopoietic Homologous Humans Male Microcirculation Middle Radiotherapy Stem Studies Time Transplantation Vascular adverse cells diagnosis effects etiology methods pathology by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model
F. R. Luo, Z. Yang, H. Dong, A. Camuso, K. McGlinchey, K. Fager, C. Flefleh, D. Kan, I. Inigo, S. Castaneda, T. W. Wong, R. A. Kramer, R. Wild, and F. Y. Lee Clin.Cancer Res. 11(15):5558-5565 (2005)
to Agents Animals Antibodies Antigen Antineoplastic Antitumor Assay Assays Biological Carcinoma Cell Chemistry Colonic Enzyme-Linked Epidermal Factor Factors Female G Growth Human Humans Immunoglobulin Immunohistochemistry Immunosorbent Ki-67 Kinase Line MAP Markers Mice Model Monoclonal Neoplasm Neoplasms Nude Pharmacokinetics Phosphorylation Receptor Research Signaling System Time Transplantation Tumor Tyrosine Xenograft analysis biosynthesis drug metabolism methods pathology pharmacology protein response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
D. J. Hicklin, and L. M. Ellis J.Clin.Oncol. 23(5):1011-1027 (2005)
to & A Agents Angiogenesis Animals Antibodies Antineoplastic Binding Endothelial Factor Growth Human Humans Inhibitors Ligands Neoplasms Neovascularization Pathologic Receptors Research Signal Transduction Vascular antagonists blood cells inhibitors physiology physiopathology response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
A. L. Harris, P. Reusch, B. Barleon, C. Hang, N. Dobbs, and D. Marme Clin.Cancer Res. 7(7):1992-1997 (2001)
to & Aged Agents Analysis Antineoplastic Assay Binding Endothelial Enzyme-Linked Factor Female Growth Humans Immunosorbent Kidney Kinase Kinases Laboratories Male Middle Multivariate Neoplasms Neovascularization Outcome Pathologic Prognosis Protein-Tyrosine Proteins Proto-Oncogene Razoxane Receptor Receptor-1 Research Sites Solubility Survival TIE-2 Treatment Tyrosine Vascular blood control drug effects pathology prevention protein response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)

<< < 1 > >>publications per page: 5 10 20 50 100

a gripper